+关注
Xiaoming96
暂无个人介绍
IP属地：未知
4
关注
1
粉丝
0
主题
0
勋章
主贴
热门
Xiaoming96
2021-01-28
Sweet
Why Moderna Stock Is Already Up 25% This Year<blockquote>为什么Moderna股价今年已上涨25%</blockquote>
Xiaoming96
2021-01-28
Nice![微笑]
抱歉，原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3570251156987024","uuid":"3570251156987024","gmtCreate":1607157510341,"gmtModify":1611800281970,"name":"Xiaoming96","pinyin":"xiaoming96","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/fbbc587d6c036df588013744ed434b66","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":4,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.19","exceedPercentage":"60.54%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":311108396,"gmtCreate":1611765028415,"gmtModify":1703753564319,"author":{"id":"3570251156987024","authorId":"3570251156987024","name":"Xiaoming96","avatar":"https://static.tigerbbs.com/fbbc587d6c036df588013744ed434b66","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570251156987024","authorIdStr":"3570251156987024"},"themes":[],"htmlText":"Sweet","listText":"Sweet","text":"Sweet","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/311108396","repostId":"1121409246","repostType":4,"repost":{"id":"1121409246","kind":"news","pubTimestamp":1611733545,"share":"https://www.laohu8.com/m/news/1121409246?lang=zh_CN&edition=full","pubTime":"2021-01-27 15:45","market":"us","language":"en","title":"Why Moderna Stock Is Already Up 25% This Year<blockquote>为什么Moderna股价今年已上涨25%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1121409246","media":"Nasdaq","summary":"Moderna (NASDAQ: MRNA)stock has rallied by almost 25% since the beginning of this year, currently tr","content":"<p>Moderna (NASDAQ: MRNA)stock has rallied by almost 25% since the beginning of this year, currently trading at levels of around $130 per share. There are a couple of developments that are likely driving the gains.</p><p><blockquote>Moderna（纳斯达克股票代码：MRNA）股价自今年年初以来已上涨近25%，目前交易价格约为每股130美元。有几个发展可能会推动收益。</blockquote></p><p>Sponsored LinksPlay the most challenging WWII strategy game, no install neededCall of War | World War II</p><p><blockquote>赞助商链接玩最具挑战性的二战策略游戏，无需安装战争召唤|二战</blockquote></p><p>Firstly, the company said that it was expanding its pipeline, developing three new vaccine candidates against seasonal flu, HIV, and the Nipah virus. Although this is seen as a relatively ambitious effort, considering that some of these diseases have eluded traditional vaccines so far, Moderna is hoping that it can address them with its mRNA technology, which has proven highly effective in the Covid-19 vaccine. The upsides from these potential vaccines could be sizable.</p><p><blockquote>首先，该公司表示正在扩大其产品线，开发三种针对季节性流感、艾滋病毒和尼帕病毒的新候选疫苗。尽管这被视为一项相对雄心勃勃的努力，但考虑到其中一些疾病迄今为止一直无法获得传统疫苗，Moderna希望能够通过其mRNA技术来解决这些问题，该技术已被证明在Covid-19疫苗中非常有效。这些潜在疫苗的好处可能是巨大的。</blockquote></p><p>Secondly, Moderna provided updates on the manufacturing of its Covid-19 vaccine, noting that it was increasing the baseline production estimate for this year to 600 million doses, 100 million more than it had initially projected while targeting as many as 1 billion doses. Rivals such as Johnson & Johnson and Novavax have faced manufacturing issues for their experimental vaccines and investors are likely pleased that Moderna is able to scale-up as planned despite its relative lack of a manufacturing track record.</p><p><blockquote>其次，Moderna提供了其Covid-19疫苗生产的最新情况，并指出它将今年的基线产量估计提高到6亿剂，比最初预测的多1亿剂，同时目标是多达10亿剂。强生公司和Novavax等竞争对手的实验性疫苗都面临着生产问题，尽管Moderna相对缺乏生产记录，但投资者可能很高兴Moderna能够按计划扩大规模。</blockquote></p><p>Separately, Moderna’s CEO said that people inoculated with its vaccine were likely to be protected against Coronavirus for at least a couple of years, putting to rest potential concerns that people would require a Covid-19 vaccine every year like a flu shot. This is also likely boosting confidence around Moderna’s vaccine and the stock.</p><p><blockquote>另外，Moderna首席执行官表示，接种其疫苗的人可能会在至少几年内免受冠状病毒的侵害，从而消除了人们每年都需要像注射流感疫苗一样接种Covid-19疫苗的潜在担忧。这也可能会增强人们对Moderna疫苗和股票的信心。</blockquote></p><p></p>","source":"lsy1603171495471","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Is Already Up 25% This Year<blockquote>为什么Moderna股价今年已上涨25%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Is Already Up 25% This Year<blockquote>为什么Moderna股价今年已上涨25%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Nasdaq</strong><span class=\"h-time small\">2021-01-27 15:45</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Moderna (NASDAQ: MRNA)stock has rallied by almost 25% since the beginning of this year, currently trading at levels of around $130 per share. There are a couple of developments that are likely driving the gains.</p><p><blockquote>Moderna（纳斯达克股票代码：MRNA）股价自今年年初以来已上涨近25%，目前交易价格约为每股130美元。有几个发展可能会推动收益。</blockquote></p><p>Sponsored LinksPlay the most challenging WWII strategy game, no install neededCall of War | World War II</p><p><blockquote>赞助商链接玩最具挑战性的二战策略游戏，无需安装战争召唤|二战</blockquote></p><p>Firstly, the company said that it was expanding its pipeline, developing three new vaccine candidates against seasonal flu, HIV, and the Nipah virus. Although this is seen as a relatively ambitious effort, considering that some of these diseases have eluded traditional vaccines so far, Moderna is hoping that it can address them with its mRNA technology, which has proven highly effective in the Covid-19 vaccine. The upsides from these potential vaccines could be sizable.</p><p><blockquote>首先，该公司表示正在扩大其产品线，开发三种针对季节性流感、艾滋病毒和尼帕病毒的新候选疫苗。尽管这被视为一项相对雄心勃勃的努力，但考虑到其中一些疾病迄今为止一直无法获得传统疫苗，Moderna希望能够通过其mRNA技术来解决这些问题，该技术已被证明在Covid-19疫苗中非常有效。这些潜在疫苗的好处可能是巨大的。</blockquote></p><p>Secondly, Moderna provided updates on the manufacturing of its Covid-19 vaccine, noting that it was increasing the baseline production estimate for this year to 600 million doses, 100 million more than it had initially projected while targeting as many as 1 billion doses. Rivals such as Johnson & Johnson and Novavax have faced manufacturing issues for their experimental vaccines and investors are likely pleased that Moderna is able to scale-up as planned despite its relative lack of a manufacturing track record.</p><p><blockquote>其次，Moderna提供了其Covid-19疫苗生产的最新情况，并指出它将今年的基线产量估计提高到6亿剂，比最初预测的多1亿剂，同时目标是多达10亿剂。强生公司和Novavax等竞争对手的实验性疫苗都面临着生产问题，尽管Moderna相对缺乏生产记录，但投资者可能很高兴Moderna能够按计划扩大规模。</blockquote></p><p>Separately, Moderna’s CEO said that people inoculated with its vaccine were likely to be protected against Coronavirus for at least a couple of years, putting to rest potential concerns that people would require a Covid-19 vaccine every year like a flu shot. This is also likely boosting confidence around Moderna’s vaccine and the stock.</p><p><blockquote>另外，Moderna首席执行官表示，接种其疫苗的人可能会在至少几年内免受冠状病毒的侵害，从而消除了人们每年都需要像注射流感疫苗一样接种Covid-19疫苗的潜在担忧。这也可能会增强人们对Moderna疫苗和股票的信心。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.nasdaq.com/articles/why-moderna-stock-is-already-up-25-this-year-2021-01-22\">Nasdaq</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.nasdaq.com/articles/why-moderna-stock-is-already-up-25-this-year-2021-01-22","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121409246","content_text":"Moderna (NASDAQ: MRNA)stock has rallied by almost 25% since the beginning of this year, currently trading at levels of around $130 per share. There are a couple of developments that are likely driving the gains.Sponsored LinksPlay the most challenging WWII strategy game, no install neededCall of War | World War IIFirstly, the company said that it was expanding its pipeline, developing three new vaccine candidates against seasonal flu, HIV, and the Nipah virus. Although this is seen as a relatively ambitious effort, considering that some of these diseases have eluded traditional vaccines so far, Moderna is hoping that it can address them with its mRNA technology, which has proven highly effective in the Covid-19 vaccine. The upsides from these potential vaccines could be sizable.Secondly, Moderna provided updates on the manufacturing of its Covid-19 vaccine, noting that it was increasing the baseline production estimate for this year to 600 million doses, 100 million more than it had initially projected while targeting as many as 1 billion doses. Rivals such as Johnson & Johnson and Novavax have faced manufacturing issues for their experimental vaccines and investors are likely pleased that Moderna is able to scale-up as planned despite its relative lack of a manufacturing track record.Separately, Moderna’s CEO said that people inoculated with its vaccine were likely to be protected against Coronavirus for at least a couple of years, putting to rest potential concerns that people would require a Covid-19 vaccine every year like a flu shot. This is also likely boosting confidence around Moderna’s vaccine and the stock.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":2823,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":311103902,"gmtCreate":1611764914406,"gmtModify":1703753561750,"author":{"id":"3570251156987024","authorId":"3570251156987024","name":"Xiaoming96","avatar":"https://static.tigerbbs.com/fbbc587d6c036df588013744ed434b66","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570251156987024","authorIdStr":"3570251156987024"},"themes":[],"htmlText":"Nice![微笑] ","listText":"Nice![微笑] ","text":"Nice![微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/311103902","repostId":"2106818182","repostType":4,"isVote":1,"tweetType":1,"viewCount":3427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":311108396,"gmtCreate":1611765028415,"gmtModify":1703753564319,"author":{"id":"3570251156987024","authorId":"3570251156987024","name":"Xiaoming96","avatar":"https://static.tigerbbs.com/fbbc587d6c036df588013744ed434b66","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570251156987024","idStr":"3570251156987024"},"themes":[],"htmlText":"Sweet","listText":"Sweet","text":"Sweet","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/311108396","repostId":"1121409246","repostType":4,"repost":{"id":"1121409246","kind":"news","pubTimestamp":1611733545,"share":"https://www.laohu8.com/m/news/1121409246?lang=zh_CN&edition=full","pubTime":"2021-01-27 15:45","market":"us","language":"en","title":"Why Moderna Stock Is Already Up 25% This Year<blockquote>为什么Moderna股价今年已上涨25%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1121409246","media":"Nasdaq","summary":"Moderna (NASDAQ: MRNA)stock has rallied by almost 25% since the beginning of this year, currently tr","content":"<p>Moderna (NASDAQ: MRNA)stock has rallied by almost 25% since the beginning of this year, currently trading at levels of around $130 per share. There are a couple of developments that are likely driving the gains.</p><p><blockquote>Moderna（纳斯达克股票代码：MRNA）股价自今年年初以来已上涨近25%，目前交易价格约为每股130美元。有几个发展可能会推动收益。</blockquote></p><p>Sponsored LinksPlay the most challenging WWII strategy game, no install neededCall of War | World War II</p><p><blockquote>赞助商链接玩最具挑战性的二战策略游戏，无需安装战争召唤|二战</blockquote></p><p>Firstly, the company said that it was expanding its pipeline, developing three new vaccine candidates against seasonal flu, HIV, and the Nipah virus. Although this is seen as a relatively ambitious effort, considering that some of these diseases have eluded traditional vaccines so far, Moderna is hoping that it can address them with its mRNA technology, which has proven highly effective in the Covid-19 vaccine. The upsides from these potential vaccines could be sizable.</p><p><blockquote>首先，该公司表示正在扩大其产品线，开发三种针对季节性流感、艾滋病毒和尼帕病毒的新候选疫苗。尽管这被视为一项相对雄心勃勃的努力，但考虑到其中一些疾病迄今为止一直无法获得传统疫苗，Moderna希望能够通过其mRNA技术来解决这些问题，该技术已被证明在Covid-19疫苗中非常有效。这些潜在疫苗的好处可能是巨大的。</blockquote></p><p>Secondly, Moderna provided updates on the manufacturing of its Covid-19 vaccine, noting that it was increasing the baseline production estimate for this year to 600 million doses, 100 million more than it had initially projected while targeting as many as 1 billion doses. Rivals such as Johnson & Johnson and Novavax have faced manufacturing issues for their experimental vaccines and investors are likely pleased that Moderna is able to scale-up as planned despite its relative lack of a manufacturing track record.</p><p><blockquote>其次，Moderna提供了其Covid-19疫苗生产的最新情况，并指出它将今年的基线产量估计提高到6亿剂，比最初预测的多1亿剂，同时目标是多达10亿剂。强生公司和Novavax等竞争对手的实验性疫苗都面临着生产问题，尽管Moderna相对缺乏生产记录，但投资者可能很高兴Moderna能够按计划扩大规模。</blockquote></p><p>Separately, Moderna’s CEO said that people inoculated with its vaccine were likely to be protected against Coronavirus for at least a couple of years, putting to rest potential concerns that people would require a Covid-19 vaccine every year like a flu shot. This is also likely boosting confidence around Moderna’s vaccine and the stock.</p><p><blockquote>另外，Moderna首席执行官表示，接种其疫苗的人可能会在至少几年内免受冠状病毒的侵害，从而消除了人们每年都需要像注射流感疫苗一样接种Covid-19疫苗的潜在担忧。这也可能会增强人们对Moderna疫苗和股票的信心。</blockquote></p><p></p>","source":"lsy1603171495471","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Is Already Up 25% This Year<blockquote>为什么Moderna股价今年已上涨25%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Is Already Up 25% This Year<blockquote>为什么Moderna股价今年已上涨25%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Nasdaq</strong><span class=\"h-time small\">2021-01-27 15:45</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Moderna (NASDAQ: MRNA)stock has rallied by almost 25% since the beginning of this year, currently trading at levels of around $130 per share. There are a couple of developments that are likely driving the gains.</p><p><blockquote>Moderna（纳斯达克股票代码：MRNA）股价自今年年初以来已上涨近25%，目前交易价格约为每股130美元。有几个发展可能会推动收益。</blockquote></p><p>Sponsored LinksPlay the most challenging WWII strategy game, no install neededCall of War | World War II</p><p><blockquote>赞助商链接玩最具挑战性的二战策略游戏，无需安装战争召唤|二战</blockquote></p><p>Firstly, the company said that it was expanding its pipeline, developing three new vaccine candidates against seasonal flu, HIV, and the Nipah virus. Although this is seen as a relatively ambitious effort, considering that some of these diseases have eluded traditional vaccines so far, Moderna is hoping that it can address them with its mRNA technology, which has proven highly effective in the Covid-19 vaccine. The upsides from these potential vaccines could be sizable.</p><p><blockquote>首先，该公司表示正在扩大其产品线，开发三种针对季节性流感、艾滋病毒和尼帕病毒的新候选疫苗。尽管这被视为一项相对雄心勃勃的努力，但考虑到其中一些疾病迄今为止一直无法获得传统疫苗，Moderna希望能够通过其mRNA技术来解决这些问题，该技术已被证明在Covid-19疫苗中非常有效。这些潜在疫苗的好处可能是巨大的。</blockquote></p><p>Secondly, Moderna provided updates on the manufacturing of its Covid-19 vaccine, noting that it was increasing the baseline production estimate for this year to 600 million doses, 100 million more than it had initially projected while targeting as many as 1 billion doses. Rivals such as Johnson & Johnson and Novavax have faced manufacturing issues for their experimental vaccines and investors are likely pleased that Moderna is able to scale-up as planned despite its relative lack of a manufacturing track record.</p><p><blockquote>其次，Moderna提供了其Covid-19疫苗生产的最新情况，并指出它将今年的基线产量估计提高到6亿剂，比最初预测的多1亿剂，同时目标是多达10亿剂。强生公司和Novavax等竞争对手的实验性疫苗都面临着生产问题，尽管Moderna相对缺乏生产记录，但投资者可能很高兴Moderna能够按计划扩大规模。</blockquote></p><p>Separately, Moderna’s CEO said that people inoculated with its vaccine were likely to be protected against Coronavirus for at least a couple of years, putting to rest potential concerns that people would require a Covid-19 vaccine every year like a flu shot. This is also likely boosting confidence around Moderna’s vaccine and the stock.</p><p><blockquote>另外，Moderna首席执行官表示，接种其疫苗的人可能会在至少几年内免受冠状病毒的侵害，从而消除了人们每年都需要像注射流感疫苗一样接种Covid-19疫苗的潜在担忧。这也可能会增强人们对Moderna疫苗和股票的信心。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.nasdaq.com/articles/why-moderna-stock-is-already-up-25-this-year-2021-01-22\">Nasdaq</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.nasdaq.com/articles/why-moderna-stock-is-already-up-25-this-year-2021-01-22","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121409246","content_text":"Moderna (NASDAQ: MRNA)stock has rallied by almost 25% since the beginning of this year, currently trading at levels of around $130 per share. There are a couple of developments that are likely driving the gains.Sponsored LinksPlay the most challenging WWII strategy game, no install neededCall of War | World War IIFirstly, the company said that it was expanding its pipeline, developing three new vaccine candidates against seasonal flu, HIV, and the Nipah virus. Although this is seen as a relatively ambitious effort, considering that some of these diseases have eluded traditional vaccines so far, Moderna is hoping that it can address them with its mRNA technology, which has proven highly effective in the Covid-19 vaccine. The upsides from these potential vaccines could be sizable.Secondly, Moderna provided updates on the manufacturing of its Covid-19 vaccine, noting that it was increasing the baseline production estimate for this year to 600 million doses, 100 million more than it had initially projected while targeting as many as 1 billion doses. Rivals such as Johnson & Johnson and Novavax have faced manufacturing issues for their experimental vaccines and investors are likely pleased that Moderna is able to scale-up as planned despite its relative lack of a manufacturing track record.Separately, Moderna’s CEO said that people inoculated with its vaccine were likely to be protected against Coronavirus for at least a couple of years, putting to rest potential concerns that people would require a Covid-19 vaccine every year like a flu shot. This is also likely boosting confidence around Moderna’s vaccine and the stock.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":2823,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":311103902,"gmtCreate":1611764914406,"gmtModify":1703753561750,"author":{"id":"3570251156987024","authorId":"3570251156987024","name":"Xiaoming96","avatar":"https://static.tigerbbs.com/fbbc587d6c036df588013744ed434b66","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570251156987024","idStr":"3570251156987024"},"themes":[],"htmlText":"Nice![微笑] ","listText":"Nice![微笑] ","text":"Nice![微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/311103902","repostId":"2106818182","repostType":4,"isVote":1,"tweetType":1,"viewCount":3427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
